Found 6 Enz. Inhib. hit(s) with Target = 'Proto-oncogene tyrosine-protein kinase receptor Ret [V804L]' and Ligand = 'BDBM84747' TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 902nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) is incubated in a total of 12.5 μL of buffer (100 mM HEPES ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 902nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 902nMAssay Description:A compound described herein can be tested in vitro for inhibition of wild-type RET and various mutant RET kinases, including e.g., RET V804L, RET V80...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 3.60E+3nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HEPES...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 4.33E+3nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines
US Patent
Blueprint Medicines
US Patent
Affinity DataIC50: 4.75E+3nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
